NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 642.22K | $90.01M | n/a | −1 |
| Q2 2026 | 152 | 0 | 75.82M | $12.77B | +5 | −6 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Ninety One UK Ltd | 434.88K | +160372.7% | $61.68M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 145.82K | -67.2% | $20.68M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 61.52K | -14.1% | $7.64M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| TD Waterhouse Canada Inc. | $8,385 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 690 holders, 94.09M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 826 sh · $130,051
Officer · 2.31K sh · $363,285
Officer · 2.15K sh · $333,030
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology